How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Lea Bucher
Advertisement
Lea Bucher is Principal at Executive Insight.
Articles by Lea Bucher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
2
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
3
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5